An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. Ethics committee approvals or an equivalent official documents must be uploaded into the dergipark system.
• For manuscripts concerning experimental researches on humans, a “Written Informed Consent to Participate and Publish” statement should included in the text.
• Written Informed Consent to Participate Publish statement and Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.
• It is the authors responsibility to carefully protect the patients anonymity. For photographs that may reveal the identity of the patients, releases signed by the patient or their legal representative should be enclosed.
• For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.

All submissions are screened by a similarity detection software (iThenticate) and the similarity limitation is 25%. The Editorial Board of the journal handles all appeal and complaint cases within the scope of Committee on Publication Ethics (COPE) guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

When submitting a manuscript to Med J SDU, authors accept to assign the copyright of their manuscript to the journal. If rejected for publication, the copyright of the manuscript is considered to be assign back to the authors. Each submission must be submitted in accordance with the journal template (available for download at: https://dergipark.org.tr/tr/download/journal-file/24521), together with a Copyright Transfer Form (available for download at: https://dergipark.org.tr/tr/download/journal-file/22117). Mandatory documents to be sent can be found at https://dergipark.org.tr/tr/pub/sdutfd.
When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s). Statements or opinions expressed in the manuscripts published in Med J SDU reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors. Revisions should submit within 15 days in pre-review stage and in 30 days in review stage. Otherwise manuscripts will be rejected